摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-hydroxy-N-(4-hydroxyphenyl)acetamide | 54704-27-7

中文名称
——
中文别名
——
英文名称
2-hydroxy-N-(4-hydroxyphenyl)acetamide
英文别名
2-Hydroxy-N-(4-hydroxy-phenyl)-acetamide
2-hydroxy-N-(4-hydroxyphenyl)acetamide化学式
CAS
54704-27-7
化学式
C8H9NO3
mdl
——
分子量
167.164
InChiKey
AFOASBUSAJOWLT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    69.6
  • 氢给体数:
    3
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-hydroxy-N-(4-hydroxyphenyl)acetamidetetrakis(acetonitrile)copper(I) perchlorate碘苯二乙酸1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下, 以 四氢呋喃二氯甲烷 为溶剂, 生成 4-methyl 1-oxa-4-azaspiro[4.5]deca-6,9-diene-3,8-dione
    参考文献:
    名称:
    一系列新型 1-Oxa-4-azaspiro[4,5]deca-6,9-diene-3,8-dione 衍生物的合成及抗肿瘤活性。
    摘要:
    以4-氨基苯酚和α-乙醇酸或乳酸为起始原料,采用三种或三种方法设计合成了一系列新型1-oxa-4-azaspiro[4.5]deca-6,9-diene-3,8-dioones。四个步骤。关键步骤是酰胺的金属催化氧化环化为 1-oxa-4-azaspiro[4.5]deca-6,9-diene-3,8-diones (10a 和 10b),研究了其反应条件并优化。评估了 17 1-oxa-4-azaspiro[4.5]deca-6,9-diene-3,8-dione 衍生物的抗癌活性。初步结果表明,15 种化合物对人肺癌 A549、人乳腺癌 MDA-MB-231 和人宫颈癌 HeLa 癌细胞系具有中度至强效活性。其中,化合物 11b 和 11h 对 A549 细胞系最有效,IC50 分别为 0.18 和 0.19 µM;化合物 11d、11h、和 11k 对 MDA-MB-231 细胞系的细胞毒性最强,IC50
    DOI:
    10.3390/molecules24050936
  • 作为产物:
    描述:
    2-benzyloxy-N-(p-hydroxyphenyl)acetamide 氢气甲醇chloroform methanol 作用下, 以 甲醇 为溶剂, 反应 8.0h, 以to get pure 27 (4 grams, 34.2%) as的产率得到2-hydroxy-N-(4-hydroxyphenyl)acetamide
    参考文献:
    名称:
    Functionalized drugs and polymers derived therefrom
    摘要:
    从中选择的化合物:其中DRUG-OH,DRUG-COOH和DRUG-NH2是生物活性化合物;每个X独立地从-CH2COO-(乙二酸醇基),-CH(CH3)COO-(乳酸醇基),-CH2CH2OCH2COO-(二氧杂环己酮基),-CH2CH2CH2CH2CH2COO-(己内酯基),-(CH2)yCOO-中选择,其中y为2-4或6-24,以及-(CH2CH2O)zCH2COO-,其中z为2-24;每个Y独立地从-COCH2O-(乙二酸酯基),-COCH(CH3)O-(乳酸酯基),-COCH2OCH2CH2O-(二氧杂环己酮酯基),-COCH2CH2CH2CH2CH2O-(己内酯酯基),-CO(CH2)mO-中选择,其中m为2-4或6-24,以及-COCH2O(CH2CH2O)n-,其中n在2-24之间;R'为氢,苄基或烷基,烷基可以是直链或支链;p为1-6。还披露了多功能化合物和药物二聚体,寡聚体和聚合物。
    公开号:
    US07691364B2
点击查看最新优质反应信息

文献信息

  • Functionalized drugs and polymers derived therefrom
    申请人:Bezwada S. Rao
    公开号:US20060172983A1
    公开(公告)日:2006-08-03
    Compounds selected from: where DRUG-OH, DRUG-COOH and DRUG-NH 2 are biologically active compounds; each X is independently selected from —CH 2 COO— (glycolic acid moiety), —CH(CH 3 )COO— (lactic acid moiety), —CH 2 CH 2 OCH 2 COO— (dioxanone moiety), —CH 2 CH 2 CH 2 CH 2 CH 2 COO— (caprolactone moiety), —(CH 2 ) y COO—, where y is 2-4 or 6-24 and —(CH 2 CH 2 O) z CH 2 COO—, where z is 2-24; each Y is independently selected from —COCH 2 O— (glycolic ester moiety), —COCH(CH 3 )O— (lactic ester moiety), —COCH 2 OCH 2 CH 2 O— (dioxanone ester moiety), —COCH 2 CH 2 CH 2 CH 2 CH 2 O— (caprolactone ester moiety), —CO(CH 2 ) m O—, where m is 2-4 or 6-24 and —COCH 2 O(CH 2 CH 2 O) n — where n is between 2-24; R′ is hydrogen, benzyl or an alkyl group, the alkyl group being either straight-chained or branched; and p is 1-6. Multi-functional compounds and drug dimers, oligomers and polymers are also disclosed.
    从中选择的化合物:其中DRUG-OH,DRUG-COOH和DRUG-NH2是生物活性化合物;每个X独立地从—CH2COO—(乙二酸基团),—CH(CH3)COO—(乳酸基团),—CH2CH2OCH2COO—(二氧杂环己酮基团),—CH2CH2CH2CH2CH2COO—(己内酯基团),—(CH2)yCOO—中选择,其中y为2-4或6-24和—(CH2CH2O)zCH2COO—,其中z为2-24;每个Y独立地从—COCH2O—(乙二酸酯基团),—COCH(CH3)O—(乳酸酯基团),—COCH2OCH2CH2O—(二氧杂环己酮酯基团),—COCH2CH2CH2CH2CH2O—(己内酯酯基团),—CO(CH2)mO—,其中m为2-4或6-24和—COCH2O(CH2CH2O)n—,其中n为2-24;R′为氢,苄基或烷基,烷基可以是直链或支链;p为1-6。还披露了多功能化合物和药物二聚体、寡聚体和聚合物。
  • Functionalized phenolic esters and amides and polymers therefrom
    申请人:Bezwada S. Rao
    公开号:US20060173065A1
    公开(公告)日:2006-08-03
    The present invention relates to a compound of the formula: R-AR—O—Y—R′ Wherein R represents one or more members selected from H, alkoxy, benzyloxy, aldehyde, halogen, carboxylic acid, —NO 2 , —NH 2 , —NHCOCH 3 , and —NH—Y—R′, which is attached directly to AR or attached through an aliphatic chain. The carboxylic acid moiety in R includes but is not limited to the following carboxylic acids: benzoic acids, cinnamic acids, ferulic acid, caffeic acid, syringic acid, salicylic acid, vanillic acid, phenylacetic acids, phenylpropionic acids, and sinapinic acid. -AR—O— is a biologically active phenolic moiety comprising 1 to 6 substituted or unsubstituted aryl rings that are directly bonded to each other, fused together, or joined through a linking group. Y represents a member selected from: —COCH 2 O— (glycolic ester moiety) —COCH(CH 3 )O— (lactic ester moiety) —COCH 2 OCH 2 CH 2 O— (dioxanone ester moiety) —COCH 2 CH 2 CH 2 CH 2 CH 2 O— (caprolactone ester moiety) —CO(CH 2 ) m O— where m is an integer between 2-4 and 6-24 inclusive —COCH 2 O(CH 2 CH 2 O) n — where n is an integer between 2 and 24, inclusive; and R′ is either hydrogen or a benzyl or an alkyl group, the alkyl group being either straight-chained or branched. The resultant functionalized phenolic compounds, used singly or in combinations, and their polymers have controllable degradation profiles, releasing the active component over a desired time range. The polymers are useful for biomaterials and biomedical devices, wherein said biologically active phenolic moiety is a residue of a phenolic compound.
    本发明涉及一种化合物,其化学式为:R-AR—O—Y—R′,其中R代表从H、烷氧基、苯甲氧基、醛基、卤素、羧酸、—NO2、—NH2、—NHCOCH3和—NH—Y—R′中选择的一个或多个成员,该成员直接附着在AR上或通过脂肪链连接。R中的羧酸基团包括但不限于以下羧酸:苯甲酸、肉桂酸、阿魏酸、咖啡酸、槲皮酸、水杨酸、香草酸、苯乙酸、苯丙酸和芥子酸。-AR—O—是一个生物活性的酚基团,包括1到6个取代或未取代的芳香环直接连接、融合或通过连接基团连接的环。Y代表从以下成员中选择:—COCH2O—(乙二醇酯基团)—COCH(CH3)O—(乳酸酯基团)—COCH2OCH2CH2O—(二氧环酮酯基团)—COCH2CH2CH2CH2CH2O—(己内酯酯基团)—CO(CH2)mO—其中m是2-4和6-24之间的整数—COCH2O(CH2CH2O)n—其中n是2到24之间的整数;R′是氢或苄基或烷基,烷基可以是直链或支链。所得的功能化酚类化合物单独或组合使用,其聚合物具有可控的降解特性,释放所需时间范围内的活性成分。该聚合物对于生物材料和生物医学器械有用,其中所述的生物活性酚基团是酚类化合物的残留物。
  • FUNCTIONALIZED DRUGS AND POLYMERS THEREFROM
    申请人:Bezwada Rao S.
    公开号:US20100152272A1
    公开(公告)日:2010-06-17
    Compounds selected from: where DRUG-OH, DRUG-COOH and DRUG-NH 2 are biologically active compounds; each X is independently selected from —CH 2 COO— (glycolic acid moiety), —CH(CH 3 )COO— (lactic acid moiety), —CH 2 CH 2 OCH 2 COO— (dioxanone moiety), —CH 2 CH 2 CH 2 CH 2 CH 2 COO— (caprolactone moiety), —(CH 2 ) y COO—, where y is 2-4 or 6-24 and —(CH 2 CH 2 O) z CH 2 COO—, where z is 2-24; each Y is independently selected from —COCH 2 O— (glycolic ester moiety), —COCH(CH 3 )O— (lactic ester moiety), —COCH 2 OCH 2 CH 2 O— (dioxanone ester moiety), —COCH 2 CH 2 CH 2 CH 2 CH 2 O— (caprolactone ester moiety), —CO(CH 2 ) m O—, where m is 2-4 or 6-24 and —COCH 2 O(CH 2 CH 2 O) n — where n is between 2-24; R′ is hydrogen, benzyl or an alkyl group, the alkyl group being either straight-chained or branched; and p is 1-6. Multi-functional compounds and drug dimers, oligomers and polymers are also disclosed.
    所选化合物包括:DRUG-OH,DRUG-COOH和DRUG-NH2是具有生物活性的化合物;每个X独立选择自—CH2COO—(乙二酸酯基),—CH(CH3)COO—(乳酸酯基),—CH2CH2OCH2COO—(二氧杂环己酮酯基),—CH2CH2CH2CH2CH2COO—(己内酯酯基),—(CH2)yCOO—,其中y为2-4或6-24和—(CH2CH2O)zCH2COO—,其中z为2-24;每个Y独立选择自—COCH2O—(乙二酸酯基),—COCH(CH3)O—(乳酸酯基),—COCH2OCH2CH2O—(二氧杂环己酮酯基),—COCH2CH2CH2CH2CH2O—(己内酯酯基),—CO(CH2)mO—,其中m为2-4或6-24和—COCH2O(CH2CH2O)n—,其中n为2-24;R'为氢,苄基或烷基,所述烷基可以是直链或支链;p为1-6。还公开了多功能化合物和药物二聚体、寡聚体和聚合物。
  • FUNCTIONALIZED PHENOLIC ESTERS AND AMIDES AND POLYMERS THEREFROM
    申请人:Bezwada Rao S.
    公开号:US20110130448A1
    公开(公告)日:2011-06-02
    The present invention relates to a compound of the formula: R-AR—O—Y—R′ Wherein R represents one or more members selected from H, alkoxy, benzyloxy, aldehyde, halogen, carboxylic acid, —NO 2 , —NH 2 , —NHCOCH 3 , and —NH—Y—R′, which is attached directly to AR or attached through an aliphatic chain. The carboxylic acid moiety in R includes but is not limited to the following carboxylic acids: benzoic acids, cinnamic acids, ferulic acid, caffeic acid, syringic acid, salicyclic acid, vanillic acid, phenylacetic acids, phenylpropionic acids, and sinapinic acid. -AR—O— is a biologically active phenolic moiety comprising 1 to 6 substituted or unsubstituted aryl rings that are directly bonded to each other, fused together, or joined through a linking group. Y represents a member selected from: —COCH 2 O— (glycolic ester moiety) —COCH(CH 3 )O— (lactic ester moiety) —COCH 2 OCH 2 CH 2 O— (dioxanone ester moiety) —COCH 2 CH 2 CH 2 CH 2 CH 2 O— (caprolactone ester moiety) —CO(CH 2 ) m O— where m is an integer between 2-4 and 6-24 inclusive —COCH 2 —O—(CH 2 CH 2 O) n — where n is an integer between 2 and 24, inclusive; and R′ is either hydrogen or a benzyl or an alkyl group, the alkyl group being either straight-chained or branched. The resultant functionalized phenolic compounds, used singly or in combinations, and their polymers have controllable degradation profiles, releasing the active component over a desired time range. The polymers are useful for biomaterials and biomedical devices, wherein said biologically active phenolic moiety is a residue of a phenolic compound.
    本发明涉及以下式的化合物:R-AR-O-Y-R′其中R代表从H、烷氧基、苯甲氧基、醛基、卤素、羧酸、-NO2、-NH2、-NHCOCH3和-NH-Y-R′中选择的一个或多个成员,它们直接连接到AR或通过脂肪链连接。R中的羧酸基团包括但不限于以下羧酸:苯甲酸、肉桂酸、香豆酸、咖啡酸、槲皮酸、水杨酸、香草酸、苯乙酸、苯丙酸和芥子酸。-AR-O-是一个生物活性酚基团,包括1至6个取代或未取代的芳环,它们直接连接在一起,融合在一起或通过连接基团连接在一起。Y代表从以下成员中选择:-COCH2O-(乙二醇酯基团)、-COCH(CH3)O-(乳酸酯基团)、-COCH2OCH2CH2O-(二氧杂环酮酯基团)、-COCH2CH2CH2CH2CH2O-(己内酯酯基团)、-CO(CH2)mO-其中m是2-4和6-24之间的整数,-COCH2-O-(CH2CH2O)n-其中n是2至24之间的整数;以及R′是氢或苄基或烷基,烷基可以是直链或支链。所得的功能化酚化合物,单独或组合使用,及其聚合物具有可控的降解特性,可以在所需的时间范围内释放活性成分。这些聚合物对于生物材料和生物医学器件非常有用,其中所述的生物活性酚基团是酚化合物的残基。
  • Design, synthesis, and antitumor study of a series of novel 1-Oxa-4-azaspironenone derivatives
    作者:Honglu Yin、Yuepeng Chen、Qiu Zhong、Shilong Zheng、Guangdi Wang、Ling He
    DOI:10.1016/j.bmcl.2022.128925
    日期:2022.10
    A series of 1-oxa-4-azaspiro[4,5]deca-6,9-diene-3,8-dione derivatives containing structural fragments of conjugated dienone have been synthesized previously by our group, however the Michael addition reaction between conjugated dienone and nucleophilic groups in the body may generate harmful and adverse effects. To reduce harmful side effects, the authors started with p-aminophenol to make 1-oxo-4-
    本课题组之前已经合成了一系列含有共轭二烯酮结构片段的1-oxa-4-azaspiro[4,5]deca-6,9-diene-3,8-dione衍生物,但共轭二烯酮之间的迈克尔加成反应二烯酮和亲核基团在体内可能产生有害和不利的影响。为了减少有害的副作用,作者从对氨基苯酚开始制备1-oxo-4-氮杂螺癸二酮衍生物,然后利用迈克尔加成和环丙烷化消除α,β不饱和烯键并降低化合物在体内的迈克尔反应性优化。同时,在分子中引入杂原子,以提高分子的亲水性以及分子与靶分子的结合位点,为提高抗肿瘤活性奠定基础。大多数化合物对 A549 人肺癌细胞、MDA-MB-231 乳腺癌细胞和 Hela 人宫颈癌细胞具有中度至强效活性。其中化合物6d对A549细胞系作用最强,IC 50为0.26 μM;化合物8d对MDA-MB-231细胞系的细胞毒性最强,IC 50为0.10 μM。化合物6b对Hela细胞系的活性最强,IC
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐